Ozempic NAION Leads

Better Than Buying Ozempic NAION Leads

Legal Calls sells exclusive Ozempic NAION leads and signed retainers to law firms. Claimants allege GLP-1 drugs such as Ozempic, Wegovy and Mounjaro caused NAION, a sudden optic-nerve injury that can cause permanent vision loss. Leads come from our own Meta, TikTok and Google ads and are delivered by CRM, API, email or warm transfer.

Ozempic NAION Leads & Signed Retainers

Superior Performance, Superior Pricing

To get a Custom Quote Today

Ozempic NAION Leads: Key Facts & Litigation Status

Ozempic NAION Leads at a Glance

Case typePharmaceutical product liability (GLP-1 receptor agonists)
LitigationMDL No. 3163, E.D. Pa., Judge Karen Spencer Marston (created Dec 15, 2025)
Alleged injuriesNAION (optic nerve “eye stroke”) with sudden, often permanent vision loss
Lead sourcesMeta, TikTok & Google ads — no affiliates
What you getExclusive leads or signed retainers
DeliveryCRM, API, email or warm transfer
IntakeIn-house team, under 1-minute speed-to-lead
ProofTrustedForm certificate, call recordings, ad account access
VolumeOn request
Last reviewedNovember 2026

Ozempic NAION Litigation Status

On December 15, 2025 the JPML centralized GLP-1 vision-loss claims in MDL No. 3163, In re: GLP-1 RAs Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation. It sits in the Eastern District of Pennsylvania before Judge Karen Spencer Marston. Defendants are Novo Nordisk and Eli Lilly.

GLP-1 gastroparesis and other GI claims are a separate track in MDL 3094, though the same judge handles both. New Jersey also has a state-court multicounty litigation for GLP-1 NAION cases in Bergen County, before Judge Gregg A. Padovano.

A July 2, 2026 case management order directed early discovery and motions on general causation and preemption/warning adequacy. As of November 2026 the MDL is in pretrial discovery, with more than 200 actions pending in fall 2026 per JPML reports. No bellwether trial dates or settlement had been announced.

On November 9, 2026 the FDA required all GLP-1 drug labels to add a warning about a potential increased risk of NAION to Warnings and Precautions. The FDA did not find that the drugs cause NAION. The timing of this warning bears on the failure-to-warn theory, especially for vision loss before it.

Sources: Separate Litigation Created for NAION Injuries Caused by GLP-1 Drugs (Pope McGlamry) · MDL 3163 Case Management Order No. 12, July 2, 2026 · FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk (Pharmacy Times) · New Jersey GLP-1 NAION Multicounty Litigation leadership (Anapol Weiss). Status as of November 2026.

What Sets Us Apart From Other Ozempic NAION Lead Vendors?

Years of Excellence
14 +
Ad Spend Managed
78 M+
Leads Delivered
390 k+

Real Customers, Real Satisfaction

Ozempic NAION Client Acquisition Example Criteria & Pricing

Criteria shown is generalized based on current standards in this mass tort. Tailored criteria sets are available to meet client specifications.

To get a Custom Quote Today

How It Works & Pricing

How Our Ozempic NAION Campaigns Work

  1. We run our own Meta, TikTok and Google ads aimed at GLP-1 users who experienced sudden vision loss.
  2. Pre-screen questions confirm the drug used, a NAION diagnosis and that it followed the start of treatment.
  3. Our in-house intake team calls within a minute to verify the eye-specialist diagnosis, timing and records.
  4. Qualified claimants are delivered to your firm by CRM, API, email or warm transfer, or as signed retainers.

Leads or Signed Retainers — Your Choice

Exclusive Ozempic NAION leads: pre-screened claimants delivered in real time to your CRM, by API, by email or as a warm transfer, for your own team to sign.

Signed Ozempic NAION retainers: our in-house intake team qualifies the claimant and collects the signed retainer and HIPAA authorization before the case is delivered.

Pricing: a percentage of ad spend, or a fixed price per signed retainer. Volume is available on request.

More about Our Ozempic NAION Client Acquisition Signed Retainers

Ozempic NAION Leads: Frequently Asked Questions

Is there an MDL for Ozempic NAION?

Yes. NAION claims are centralized in MDL No. 3163 in the Eastern District of Pennsylvania before Judge Karen Spencer Marston, created on December 15, 2025. It is separate from the GLP-1 gastrointestinal MDL 3094.

What injuries qualify?

The core injury is non-arteritic anterior ischemic optic neuropathy (NAION), usually sudden and painless vision loss in one or both eyes. Intake focuses on an eye-specialist NAION diagnosis made after GLP-1 use began.

Which drugs are covered?

The MDL involves Novo Nordisk drugs (Ozempic, Wegovy, Rybelsus, Saxenda) and Eli Lilly drugs (Mounjaro, Zepbound, Trulicity).

Is NAION on the GLP-1 warning labels?

It is being added. On November 9, 2026 the FDA required all GLP-1 labels to warn of a potential increased risk of NAION. The FDA did not conclude the drugs cause NAION.

Are your Ozempic NAION leads exclusive?

Yes. Each lead is sold to one firm only and comes from our own ads, not affiliates, with a TrustedForm certificate and call recording.

Do you sell signed Ozempic NAION retainers?

Yes. Firms can buy exclusive leads or signed retainers, priced as a percentage of ad spend or a fixed price per signed retainer.

Related Mass Tort Leads

Ozempic Gastroparesis Leads · Ozempic Leads · Depo-Provera Leads · Mass Tort Intake · All mass tort case leads

Are You Price-Shopping for Ozempic NAION Leads?

Prices are always changing and tend to rise over time. We work with you to get the lowest client acquisition cost in the industry by tailoring our service to your needs.

Book a time with our VP, and he’ll walk you through pricing and strategy step by step.